Agonist-mediated activation of the type 1 parathyroid hormone receptor (PTH1R) results in several signaling events, and receptor endocytosis. It is well documented that arrestins contribute to desensitization of both G s -and G q -mediated signaling and mediate PTH1R internalization. However, whether PTH1R trafficking directly contributes to signaling remains unclear. To address this, we investigated the role of PTH1R trafficking in cAMP signaling and activation of extracellular signal-regulated kinases ERK1/2 in HEK-293 cells. Dominant-negative forms of dynamin (K44A-dynamin) and β β β β-arrestin1 (β β β β-arrestin1(319-418)) abrogated PTH1R internalization but had no effect on cAMP signaling: neither acute cAMP production by PTH, nor desensitization and resensitization of cAMP signaling were affected. Therefore, PTH1R trafficking is not necessary for regulation of cAMP signaling. PTH(1-34) induced rapid and robust activation of ERK1/2. A PTHrP-based analog (Bpa 1 -PTHrP-(1-36)) that selectively activates the G s /cAMP pathway without inducing PTH1R endocytosis, failed to stimulate ERK1/2 activity. Inhibition of PTH1R endocytosis by K44A-dynamin dampened ERK1/2 activation in response to PTH(1-34) by 69%. Incubation with the EGF receptor inhibitor AG1478 reduced ERK1/2 phosphorylation further. In addition, ERK1/2 phosphorylation occurred following internalization of a PTH1R mutant induced by PTH(7-34) in the absence of G protein signaling. Collectively, these data indicate that PTH1R trafficking and G q (but not G s ) signaling independently contribute to ERK1/2 activation, predominantly via transactivation of the EGFR.
INTRODUCTION
Parathyroid hormone (PTH) 1 is the primary regulator of serum calcium homeostasis and bone metabolism. In response to low blood calcium levels, PTH is released into the circulation and acts primarily on the receptor for PTH/PTHrP (PTH1R) in bone and kidney (1) . Parathyroid hormone-related peptide (PTHrP) was first described as the hormone responsible for hypercalcemia of malignancy (2) (3) (4) , and has subsequently been described as having a role in both cell proliferation and differentiation (5) .
The identification of the PTH1R as a seven transmembrane class II G protein-coupled receptor (GPCR) (6) was followed shortly thereafter by the elucidation of associated signaling mechanisms (7, 8) . Upon stimulation with either PTH or PTHrP, a G protein-mediated cascade of events occurs via G s and G q resulting in the activation of the cAMP/PKA and PLC/PKC pathways, respectively. In turn, these events lead to receptor phosphorylation (9-11) and β-arrestin recruitment coupled to receptor desensitization (12) (13) (14) . Agonist-receptor complex internalization then occurs via clathrin-coated pits in a β-arrestindependent manner (12, 15) .
Many of the actions of PTH are mediated by cAMP, including its well-established skeletal anabolic action (16) . We have demonstrated that regulation of cAMP production by the PTH1R is predominantly under the control of β-arrestins (12, 15) . PTH1R activation is rapidly followed by arrestin recruitment to the cell membrane and 2 consequent receptor desensitization (12, 15, 17) . Although arrestin-mediated PTH1R desensitization is probably independent of receptor internalization, this has not been firmly demonstrated. In fact, whether PTH1R trafficking contributes at all to the ability of the receptor to generate cAMP is at present unknown.
Many cellular effects of PTH and PTHrP are also partly dependent on the activation of the mitogen-activated protein kinases (MAPK), ERK1 and ERK2 (ERK1/2). Activation of ERK1/2 has been described in various target cells, including osteoblasts, bone marrow cells and distal/proximal convoluted tubule kidney cells. In these cells, ERK1/2 activation is associated with differentiation, proliferation, survival and calcium transport (18) (19) (20) (21) (22) (23) (24) . The molecular mechanisms mediating regulation of ERK1/2 by PTH and PTHrP have been examined by several investigators.
Goltzman and Partridge independently found that PTH1R-mediated ERK1/2 activation is PKC-dependent (21, 22) . In contrast, cAMP-mediated attenuation of ERK1/2 activation for the PTH1R observed in osteoblasts, stromal cells, and osteogenic cells results in antiproliferative actions (18, 25) , and cellular apoptosis (23, 26) . In addition, transactivation of the ubiquitously expressed epidermal growth factor receptor (EGFR) has been shown to contribute to PTH1R-mediated ERK1/2 activation (24) . Clearly, a balance exists between G s -and G q -mediated signaling pathways, and EGFR transactivation in ERK1/2 activation. However, it still remains unclear whether activation of ERK1/2 occurs via trafficking-dependent or independent mechanisms. Furthermore, the mechanisms that couple G protein-mediated signaling, and receptor trafficking, to the underlying activation of MAPKs are yet to be fully elucidated.
Here, we determine that PTH1R endocytosis occurs exclusively via both a β-arrestin-and dynamin-dependent mechanism in HEK-293 cells. While PTH1R trafficking is not required for the regulation of cAMP signaling, we demonstrate that arrestin-and dynamin-dependent PTH1R internalization and G q signaling independently contribute to ERK1/2 activation, predominantly by transactivation of the EGFR.
MATERIALS AND METHODS

Materials
Anti-p44/p42 MAP kinase (ERK1/2) and Phospho-p44/p42 MAP Kinase (pERK1/2) (Thr202/Tyr204) rabbit polyclonal antibodies, and horseradish peroxidase-conjugated goat anti-rabbit antibody were purchased from Cell Signaling Technology (Beverly, MA). Alexa546-tagged goat anti-rabbit antibody was obtained from Molecular Probes (Eugene, OR). Tyrphostin AG1478 and Protease Inhibitor Cocktail Set I were obtained from Calbiochem (San Diego, CA). DMEM was from Cambrex BioScience (Walkersville, MD). Both FBS and penicillin-streptomycin were from Invitrogen (Carlsbad, CA). Human epidermal growth factor (EGF) and all other reagents were from Sigma-Aldrich (St. Louis, MI).
Cell Culture
Human embryonic kidney cells (HEK-293) were cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin in a humidified 5% CO 2 /95% air incubator at 37 o C. Cells were plated at 1.0 x 10 5 cells/well in 24-well plastic dishes (Corning Inc., Corning, NY) for adenylyl cyclase, radioligand binding, and radioligand internalization assays, and transfected as previously described (15) . Cells were plated at 1.0 x 10 5 cells/well in 6-well plastic dishes (Costar, Corning, NY) for MAPK assays, transfected and then serum starved overnight prior to performing the assay. All subsequent experiments were performed 24 h after transfection.
Peptides
The 36) ), PTH-(7-34)-NH 2 , and rhodamine-labeled PTH(1-34) and PTH(7-34) were performed as previously described (12) . The pure products were characterized by analytical HPLC, electron spray mass spectrometry, and amino acid analysis. Radioiodination and HPLC purification of PTH(1-34) was carried out as previously described (12) .
Radioligand binding and internalization
Radioligand-receptor binding and internalization assays were performed as previously described (19, 31) 34) ). The binding affinity of PTH in the presence or absence of either wild-type or dominant-negative dynamin was determined by Scatchard analysis of radioreceptor binding assays performed in triplicate as described previously (12, 15) .
Adenylyl Cyclase Activity
Cyclic AMP accumulation was determined in subconfluent cell cultures in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) as previously described (15, 27) . Briefly, cells were pretreated with either vehicle (0.1% BSA in PBS) or PTH(1-34) for 30 min, followed by a 2 h washout at 37 o C in cell culture medium containing [ 3 H]-adenine (2 µCi/ml). Subsequently, the acute response and resensitization of cAMP signaling was determined in the presence of IBMX (1 mM) by PTH(1-34) stimulation for 30 min of unstimulated cells and PTH(1-34)-pretreated cells, respectively. Residual cAMP accumulation was measured for 30 min in the presence of IBMX (1 mM) in PTH(1-34)-pretreated cells. In all cases, reactions were stopped with 1.2 M trichloroacetic acid, and cAMP was isolated by the two-column chromatographic method. In some experiments, in order to prevent de novo synthesis of PTH1R, cells were preincubated for 2 h with cycloheximide (25 µg/ml) at 37 o C and maintained in the presence of cycloheximide for the duration of the experiment.
ERK1/2 Phosphorylation Assays
Cells were incubated for 18-24 hours in DMEM/0.1% BSA. Peptide treatments were carried out for the times indicated (2-30 min), after which cells were washed once in ice-cold PBS and solubilized in 300 µl NP-40 lysis buffer (1% NP-40, 150 mM NaCl, 50 mM Tris, pH 8.0 supplemented with protease inhibitor cocktail set I, and phosphatase inhibitors (1 mM sodium orthovanadate, 10 mM sodium fluoride, 10 mM glycerophosphate). Cell lysates were incubated for 20 min, and subsequently centrifuged at 12,000 rpm for 10 min at 4 o C. Cellular debris was then removed, cell lysates were resuspended in 2x Laemmli buffer and resolved by 12% SDS-PAGE. The proteins were transferred to nitrocellulose at 250 mA for 1.5 h at 4 o C. Blots were blocked for 1 h at room temperature using TBS-blocking solution containing 5% w/v milk powder, 0.1% (v/v) Tween-20. Subsequently, blots were immunoblotted with 1:1000 phospho-p44/p42 MAP Kinase (Thr202/Tyr204) rabbit polyclonal antibody for 1 h at room temperature, extensively washed (TBS-blocking solution deficient in milk powder) followed by incubation in secondary antibody (1:2000; horseradish peroxidaseconjugated goat anti-rabbit IgG). After detection of phosphorylated ERK1/2 bands by chemiluminescence and autoradiography, the membranes were stripped with 1 M glycine, pH 2.3-2.6 for 30 min at room temperature, rinsed with wash buffer, and immunoblotted as above with 1:1000 anti-p44/p42 MAP kinase rabbit polyclonal antibody. Autoradiographs were digitized and subsequent analyses were performed with Image J software (National Institutes of Health USA).
Fluorescence microscopy
For fluorescence microscopy studies with rhodamine-labeled PTH(1-34) and PTH , HEK293 cells were plated on 25-mm glass coverslips (1.5 × 10 5 cells/coverslip), transfected with the indicated GFP-tagged PTH1Rs as described above, and cultured for 24 h. Coverslips were then rinsed twice in DMEM/10% FBS, and incubated with 100 nM of the fluorescent peptides for 15 min at 37 o C. The unbound ligands were subsequently removed by washing three times with cold PBS, and coverslips were fixed using 2% paraformaldehyde for 30 min on ice. For immunofluorescence studies of ERK1/2 activation, HEK-293 cells transiently expressing the GFP-tagged PTH1R (PTH1R-GFP) were grown on glass coverslips as described above. Cells were then treated as detailed in the figure legends with 100 nM PTH(1-34), transferred to ice, rinsed in PBS, and fixed and permeabilized using a 2% paraformaldehyde/0.2% Triton X-100 solution for 30 min. Blocking was performed by incubating the cells for 10 min at room temperature in 4% FBS. Primary antibody (antiphospho-p44/p42 MAP Kinase (Thr202/Tyr204) rabbit polyclonal antibody), diluted 1:250 in PBS/1% BSA, was applied to the specimens for 1 h at room temperature, followed by three washes with the same buffer. Alexa546-tagged secondary antibody was diluted 1:200 and applied in the same conditions as the primary antibody. Coverslips were then rinsed in PBS and mounted for immunofluorescence microscopy. Coverslips were analyzed with a Zeiss LSM5 Pascal confocal microscope with a 63x-oil immersion objective (Carl Zeiss, Thornwood, NY).
Statistics
Data are presented as means ± SEM (n), where n indicates the number of independent experiments. Statistical analyses were performed using either two-tailed Student's t-test or one-way analysis of variance (ANOVA).
RESULTS
Effect of dominant-negative forms of β-arrestin
and dynamin on PTH1R internalization.
Previously described dominant-negative forms of β-arrestin1 (28) and dynamin (29) were tested for their effects on PTH-induced PTH1R internalization. PTH1R was cotransfected with either β-arrestin1(319-418) or K44A-dynamin in HEK-293 cells. Radioligand internalization assays were performed ( Figures 1A, 2A) . In control cells (cotransfection with empty vector pcDNA3), PTH1R was rapidly internalized (82 ± 8% after 45 min). In the presence of β-arrestin1(319-418), receptor endocytosis was significantly inhibited compared to control conditions, such that 45 min after agonist stimulation only 34 ± 1% was internalized (P<0.005). Similarly, in the presence of K44A-dynamin, receptor endocytosis was significantly inhibited compared to control conditions, such that 45 min after agonist stimulation only 30 ± 1% was internalized (P<0.005). Furthermore, membrane expression and affinity of 125 I-PTH(1-34) to the PTH1R under control conditions, or in the presence of either wild-type or K44A-dynamin, were equivalent irrespective of the plasmid combination used (K d was 13 ± 1, 18 ± 2 and 22 ± 4, respectively).
and dynamin on cAMP signaling.
To address whether PTH1R trafficking affected receptor signaling, we investigated the effect of either β-arrestin1(319-418) or K44A-dynamin on cAMP accumulation in HEK-293 cells ( Figure 1B, 2B ). Exposure of HEK-293 transiently expressing PTH1R to PTH(1-34) (100 nM) for 30 min resulted in a 10-fold increase in acute levels of cAMP accumulation over basal. Identical cAMP levels were measured in the presence of β-arrestin1(319-418). In addition, following the 2 h washout period the residual cAMP accumulation was 18 ± 2% and 24 ± 5% of the acute response in the absence or presence of β-arrestin1(319-418), respectively, indicating that receptor desensitization had occurred (P<0.005). Similarly, the receptor resensitized both in the absence (83 ± 5%) or presence (93 ± 3%) of β-arrestin1(319-418) compared to the acute response. Similar results were obtained in the presence of cycloheximide (25 µg/ml) (data not shown). Exposure of HEK-293 transiently coexpressing K44A-dynamin and PTH1R to PTH(1-34) (100 nM) for 30 min resulted in a 9-fold increase in acute levels of cAMP accumulation over basal. Following the 2 h washout period the residual cAMP accumulation was approximately half-maximal of the acute response in the absence (50 ± 5%) or presence (41 ± 8%) of K44A-dynamin, indicating that receptor desensitization had occurred (P<0.005). Receptor resensitization was also similar in the absence (117 ± 4%) or presence (120 ± 12%) of K44A-dynamin. In the presence of cyclohexamide (25 µg/ml), K44A-dynamin had no effect on cAMP accumulation: the receptor desensitized (60 ± 8%) and resensitized (117 ± 12%) similar to control conditions.
Collectively, these data suggest that although β-arrestin and dynamin are required for internalization of PTH1R, PTH1R trafficking is not necessary for regulation of cAMP signaling.
PTH1R-mediated ERK1/2 activation.
PTH(1-34) stimulated ERK1/2 activation in a time-dependent manner ( Figure 3) . Figure 3A shows an illustrative example of a MAPK assay over a 30 min time period; the data from several experiments are summarized in Figure 3B . These data demonstrate the rapid activation of ERK1/2 in response to PTH(1-34) stimulation. After 2-5 min ERK1/2 activation reached a peak (P<0.05 vs. basal), and then declined gradually over a 30 min time period.
To begin to elucidate the mechanisms involved in PTH1R-mediated activation of ERK1/2 we utilized a signaling-selective PTHrPbased analog (Bpa 1 -PTHrP-(1-36)) that acts solely via G s -mediated signaling (30) . In addition, it does not internalize PTH1R since it fails to induce β-arrestin2 mobilization, and thereby acts via a mechanism independent of receptor trafficking. We compared the activation of ERK1/2 in response to both PTH(1-34) and Bpa 1 -PTHrP-(1-36) (Figure 4) . As described previously, PTH(1-34) caused a 4.5 ± 0.8-fold activation of ERK1/2 after 5 min, which decreased by 30 min (2.6 ± 1.2-fold over basal). In contrast, stimulation with the G s -selective analog, Bpa 1 -PTHrP-(1-36) for 5 or 30 min, failed to induce ERK1/2 phosphorylation (resulting in only a 0.9 ± 0.1-fold and 0.9 ± 0.5-fold increase in ERK1/2 activation over basal, respectively, P<0.005 vs. PTH ).
Collectively, these data demonstrate that G smediated signaling is insufficient for ERK1/2 activation. Furthermore, a role for G q -mediated signaling and PTH1R trafficking in ERK1/2 phosphorylation is implicated by these results.
PTH1R trafficking and Gq-signaling contribute to ERK1/2 phosphorylation via transactivation of EGFR.
Previous reports have implicated the complex involvement of receptor phosphorylation, β-arrestin recruitment, and clathrin-mediated endocytosis in MAPK activation by GPCRs (31) (32) (33) (34) (35) (36) (37) . Therefore, we investigated the role of PTH1R trafficking in the activation of ERK1/2. In HEK293 cells transiently expressing PTH1R, PTH(1-34) (100 nM) stimulated an average 3.9 ± 0.6-fold increase in ERK1/2 phosphorylation over basal (n=9). Overexpression of K44A-dynamin at levels that abrogated PTH1R endocytosis without affecting signaling (Figure 2 ), reduced the PTHstimulated increase in phosphorylated ERK1/2 to an average of 1.9 ± 0.3 of basal (n=6; P<0.05) ( Figure 5 ), indicating that PTH1R trafficking contributes to ERK1/2 activation. Furthermore, to test whether ERK1/2 activation resulted from transactivation of EGFR (24), we tested the effect of tyrphostin AG1478, a selective EGFR inhibitor, on ERK1/2 activation in response to PTH(1-34).
Tyrphostin AG1478 (100 nM) significantly reduced PTH-induced ERK1/2 activation to an average 1.1 ± 0.2-fold (n=3). Tyrphostin AG1478 further reduced PTH-induced ERK1/2 phosphorylation in the presence of K44A-dynamin to 0.9 ± 0.2-fold (n=3).
Further confirmation for the presence of an EGFR-mediated mechanism linking PTH1R stimulation to ERK1/2 phosphorylation was obtained by fluorescence microscopy studies. Figure 6 shows confocal microscopy images of HEK-293 cells transfected with PTH1R-GFP either under basal conditions or following stimulation with 100 nM PTH , arrow p) , suggesting that both autocrine and paracrine events concomitant to PTH1R endocytosis contribute to ERK1/2 activation. To specifically address whether transfection affected EGFR function, we examined the direct effect of EGF on ERK1/2 activation under our experimental conditions ( Figure 7) . Following 5 min stimulation with EGF (10 ng/ml), a robust activation of ERK1/2 was observed, which could be inhibited by tyrphostin AG1478 (100 nM). However, neither K44A-dynamin nor β-arrestin1(319-418) affected ERK1/2 activation in response to EGF, indicating that the effects of dominant negative dynamin and arrestin on PTH-stimulated ERK1/2 activation are due to impaired trafficking of PTH1R.
Activation-independent ERK1/2 phosphorylation by PTH1R.
We previously characterized a point mutation in the C-terminus of the PTH1R where the terminal methionine 593 is replaced by alanine (M593A). This mutant receptor does not require activation for endocytosis to occur in distal convoluted tubule cells (38) . To confirm activation-independent PTH1R internalization in HEK293 cells, we examined the internalization of GFP epitope-tagged wild-type or mutant (M593A) PTH1R in response to 15 min stimulation with rhodamine (Rho)-labeled agonist PTH(1-34) or antagonist PTH(7-34) ( Figure 8A ). Both wild-type and M593A-PTH1R were rapidly internalized in response to Rho-PTH(1-34) (100 nM) and both ligand and receptor co-localized intracellularly (left panels). In contrast, Rho-PTH(7-34) (100 nM) bound to the wild type PTH1R-GFP on the cell membrane but did not induce internalization (top right panel). However, and similar to the agonist PTH(1-34), Rho-PTH(7-34) (100 nM) stimulated M593A-PTH1R-GFP internalization (bottom right panel). We then examined whether stimulation of M593A-PTH1R by either PTH agonist or antagonist was able to induce ERK1/2 phosphorylation ( Figure 8B and C). PTH(1-34) (100 nM) induced ERK1/2 activation for both the wild-type and the M593A-PTH1R (4.8 ± 1.4 and 2.3 ± 0.5 fold over basal, respectively). PTH(7-34) (100 nM) had little effect on ERK1/2 phosphorylation in cells expressing PTH1R (24 ± 7% of PTH(1-34)-induced ERK1/2 activation). In contrast, PTH(7-34) stimulation of the M593A-PTH1R resulted in robust ERK1/2 activation (77 ± 11% of PTH(1-34)-induced ERK1/2 activation). These data indicate that induction of PTH1R endocytosis in the absence of detectable G proteinmediated signaling is sufficient to induce ERK1/2 phosphorylation.
DISCUSSION
Several studies from different groups document that upon agonist occupancy PTH1Rs are internalized and recycle to the cell membrane (12, 14, 15, 39) . However, the functional significance of PTH1R trafficking for the overall signaling activity of, and cellular responses to PTH and PTHrP remains unclear. The goal of this study was to determine the contribution of PTH1R trafficking to signal transduction in response to PTH. First, we examined the effect of inhibition of PTH1R endocytosis on cAMP activity. In HEK293 cells, PTH1R endocytosis occurs almost exclusively through an arrestin-and dynamindependent pathway, since overexpression of dominant negative forms of either molecule largely inhibits PTH1R internalization. In these conditions, expression and affinity of the PTH1R for PTH were unchanged, as was the acute cAMP production in response to PTH. Interestingly, desensitization of cAMP signaling was also unaffected by inhibition of PTH1R internalization, indicating that receptor sequestration does not contribute to desensitization. Rather, these data demonstrate that desensitization of cAMP signaling is exclusively dependent of the interaction between receptor and arrestin at the cell membrane. For many GPCRs, internalization and recycling are fundamental steps to recover responsiveness to further stimulation (receptor resensitization) (40) . Surprisingly, we found this not to be the case for the PTH1R, since inhibition of receptor endocytosis did not affect the ability of desensitized PTH1R to fully resensitize. Therefore, cellular trafficking of PTH1R does not contribute either to desensitization or resensitization of G s -mediated cAMP activity.
PTH has been shown to regulate activity of MAPKs, specifically the extracellular-signal regulated ERK1/2, in a variety of endocrine target cells resulting in effects on proliferation, differentiation or apoptosis (18) (19) (20) (21) (22) (23) (24) (25) (26) 41) . ERK1/2 activation via GPCRs involves a variety of independent, but not necessarily exclusive, mechanisms including; (i) receptor endocytosis (31-37) (ii) G protein-mediated signaling (18, 22, 25, 35, 36) , and (iii) transactivation of tyrosine kinase receptors (24, 29, 32, (42) (43) (44) . In particular for Class II GPCRs (including the PTH1R), that are able to couple to multiple G proteins, the contribution of different pathways to ERK1/2 activation is likely to depend on the particular receptor, the cell type, the relative contribution of opposing G s -and G q -mediated signaling, and the ability to undergo endocytosis.
To address these questions, we investigated the role of PTH1R signaling and trafficking in the activation of ERK1/2. We have previously shown that modifications of residue 1 in the biologically active N-terminal fragment of PTHrP result in ligands (e.g. PTHrP(2-36) and Bpa 1 -PTHrP(1-36)) that are unable to stimulate G q /PLC/PKC-mediated signaling but still cause cAMP accumulation as a result of G s -signaling (30) . In addition, these analogs fail to stimulate translocation of β-arrestin2 to the cell membrane with a resultant absence of PTH1R endocytosis. Therefore, we used Bpa 1 -PTHrP(1-36) as a pharmacological tool to address the role of G s -mediated signaling in the activation of MAPK. In our studies, selective G s activation of PTH1R failed to activate ERK1/2. Indeed, several studies have suggested that G s /cAMP/PKA-mediated signaling inhibits ERK1/2 activity and results in reduced cell proliferation (18, 22, 25, 45) . These observations indicate that G q -mediated signaling and/or receptor trafficking are necessary for activating ERK1/2. In order to dissect the relative contribution of G qmediated signaling and PTH1R trafficking to ERK1/2 activation we used two distinct approaches.
Inhibition of PTH1R endocytosis by K44A-dynamin, leaving the ability to signal via G proteins unaffected, resulted in significant reduction of ERK1/2 activation in response to PTH, demonstrating that receptor endocytosis directly contributes to PTH signaling. In agreement with our findings, several reports have demonstrated that inhibition of dynamin partially inhibits MAPK activation by GPCRs, including β-adrenergic (31), serotonin 1A (32), δ-opioid (43), gonadotropin-releasing hormone (34, 35) , and thyrotropin-releasing hormone (36) receptors. On the other hand, to determine directly whether PTH1R endocytosis alone is sufficient to induce ERK1/2 activation, we used a mutant form of PTH1R (M593A-PTH1R) where the PDZ-binding domain is disrupted by a point mutation of the Nterminal methionine. This mutation results in a receptor that is internalized in an activationindependent manner in response to PTH(7-34) and naturally circulating PTH(7-84) (38) . In our studies, phosphorylation of ERK1/2 by M593A-PTH1R occurred in response to both PTH(1-34) and PTH . In contrast, ERK1/2 phosphorylation by wild-type PTH1R occurred in response to the agonist PTH(1-34) only. Therefore, stimulation of PTH1R endocytosis in the absence of G-protein-mediated signaling is sufficient to induce ERK1/2 activation. It is noteworthy that both approaches (the inhibition of PTH1R trafficking by K44A-dynamin and the use of the combination of M593A-PTH1R and PTH(7-34)) resulted in quantitatively comparable effects: in both cases the contribution of PTH1R trafficking is 70-80% of the total ERK1/2 activity. Nonetheless, it is plausible that different cellular environment (such as receptor density, efficacy of G s vs. G q coupling, and efficiency of the endocytic machinery) would result in differences in the relative importance of the signaling and trafficking components for ERK1/2 activation.
Collectively, these observations indicate that G q -mediated signaling and receptor endocytosis independently contribute to ERK1/2 activation by the PTH1R. Mechanistically, both signals converge to induce EGF receptor transactivation, since the inhibitor tyrphostin AG1478 abolished ERK1/2 activation by PTH, either alone or in combination with K44A-dynamin. Moreover, and in agreement with the findings of Luttrell et al. in primary osteoblasts (24), our evidence indicates that both autocrine and paracrine events occur, presumably originating from the release of soluble factors (including heparin-bound EGF) from the cell surface (known as "ectodomain shedding") following proteolysis by membrane metalloproteases (46) . Heparin-bound EGF undergoes shedding in response to stimulation of G q -coupled receptors (47) (48) (49) ). While we demonstrate in HEK-293 cells that cross talk between EGFR and PTH1R represents the predominant mechanism of PTH1R-mediated activation of ERK1/2, we also show that G q and trafficking contribute independently to this mechanism. Our data suggest that parallel, yet independent, pathways exist with G q -mediated and trafficking-dependent components.
In conclusion, we demonstrate that in HEK293 cells PTH1R endocytosis occurs exclusively via β-arrestin-and dynamin-dependent mechanisms. PTH1R trafficking affects neither acute cAMP signaling nor desensitization and resensitization of G s signals. In contrast, we show that both G q -signaling and PTH1R trafficking contribute to the activation of ERK1 and ERK2 through transactivation of EGFR. Given the complexity and variety of mechanisms involved in PTH1R-mediated ERK1/2 phosphorylation, it is not surprising that many effects, in particular the mitogenic activity, of PTH and PTHrP are remarkably cell-specific. Understanding these mechanisms will allow us to determine the overall contributions of each of these components to the physiological effects of PTH and PTHrP in tissues as diverse as bone, kidney and vasculature. Figure 1 . Effect of β β β β-arrestin1(319-418) on agonist-stimulated PTH1R internalization and cAMP accumulation. A, internalization of radiolabeled PTH . HEK-293 cells were transiently cotransfected with PTH1R (0.2 µg DNA/well) and either pcDNA3 ( ), or β-arrestin1(319-418) ( )) (0.5 µg DNA/well). Each point represents the mean percentage ± SEM of total cell-associated ligand from triplicate experiments. Average values of all experiments for internalization at 45 min were as follows: PTH1R + pcDNA3, 82 ± 8% of the total cell-associated radioligand; PTH1R + β-arrestin1(319-418), 34 ± 1% (*p < 0.005 compared to PTH1R + pcDNA3). B, a dominant-negative form of β-arrestin had no effect on cAMP signaling. HEK-293 cells transiently expressing PTH1R (0.2 µg DNA/well) and either pcDNA3 ( ) or β-arrestin (319-418) ( ) (0.5 µg DNA/well) were treated with either vehicle (0.1% BSA) or PTH(1-34) (100 nM) for 30 min, followed by a 2 h washout at 37 o C. Re-challenged and residual cAMP accumulation was then measured for 30 min in the presence of IBMX (1 mM) with or without reexposure to PTH(1-34), respectively. Results are presented as mean ± SEM from three independent experiments (*P < 0.005 compared to acute PTH(1-34) response). . Average values of all experiments for internalization at 45 min were as follows: PTH1R + pcDNA3, 78 ± 4% of the total cell-associated radioligand; PTH1R + K44A, 30 ± 1% (*p < 0.005 compared with PTH1R + pcDNA3). B, a dominant-negative form of dynamin had no effect on cAMP signaling. HEK-293 cells transiently expressing PTH1R (0.2 µg DNA/well) and either pcDNA3 ( ) or K44A-dynamin ( ) (0.5 µg DNA/well) were treated with either vehicle (0.1% BSA) or PTH(1-34) (100 nM) for 30 min, followed by a 2 h washout at 37 o C. Re-challenged and residual cAMP accumulation was then measured for 30 min in the presence of IBMX (1 mM) with or without re-exposure to PTH(1-34), respectively. Cyclic AMP accumulation was also measured in the presence of cycloheximide (25 µg/ml) ( ) to prevent de novo protein synthesis. Results are presented as mean ± SEM from three independent experiments (*P < 0.005 compared to acute PTH(1-34) response). C.
